LQDA Liquidia Corporation

Liquidia Announces Proposed Offering of Common Stock

Liquidia Announces Proposed Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced today that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a standard 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies is acting as the sole book-running manager for the proposed offering. Needham & Company and Wedbush PacGrow are acting as co-managers.

The shares of common stock described above are being offered by Liquidia pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Liquidia with the Securities and Exchange Commission (the “SEC”) on August 23, 2019 and declared effective by the SEC on September 10, 2019. The proposed offering will be made only by means of a written prospectus and prospectus supplement that form part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at When available, a copy of the preliminary prospectus relating to the proposed offering may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at .

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact Information



Investors:

Jason Adair

Vice President, Corporate Development and Strategy

919.328.4400

Media:

Michael Parks

Corporate Communications

484.356.7105

EN
29/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE

Liquidia Corporation Provides Update on Litigation Filed by United The...

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patentDoes not impact FDA’s ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company develop...

 PRESS RELEASE

Liquidia Corporation Reports First Quarter 2025 Financial Results and ...

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a...

 PRESS RELEASE

Liquidia Corporation to Present at BofA Securities 2025 Health Care Co...

Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company’s Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET ...

 PRESS RELEASE

District Court Dismisses Dispute Filed by United Therapeutics Against ...

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Co...

 PRESS RELEASE

Liquidia Corporation to Report First Quarter 2025 Financial Results on...

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at . A rebroadcast of the event will...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch